

1 **Analysis of virulence factors and *emm* typing of *Streptococcus pyogenes* clinical isolates.**

2

3 **Authors:** Gustavo E. Sambrano¹, Gustavo P. Riboldi², Keli C. Reiter¹, Thiago G. S. Paim¹, Neidimar C.
4 C. Tolfo¹, Renata O. Soares¹, Pedro A. d'Azevedo¹.

5

6

7 ¹Laboratório de Cocos Gram-positivos, Universidade Federal de Ciências da Saúde de Porto Alegre,
8 Porto Alegre, Rio Grande do Sul, Brazil.

9 ²Center for Medicinal Chemistry of Open Innovation, UNICAMP, Campinas, São Paulo, Brazil.

10

11

12 **Corresponding author:**

13 Gustavo Enck Sambrano;

14 245, Sarmiento Leite Street, Porto Alegre, RS, Zip code: 90050-170, Brazil.

15 E-mail address: gustavo.sambrano@gmail.com.

16

17

18

19

20

21

22

23

24

25

26 **Abstract**

27 **Background:** *Streptococcus pyogenes*, a Group A streptococci (GAS), is an important human
28 pathogen that causes a wide range of infections.

29 **Methods:** Twenty five clinical isolates of *S. pyogenes* were submitted to an *emm* typing and to a
30 Real-time PCR analysis for 23 important virulence factors.

31 **Results:** Fourteen *emm* types were found and the *emm1* type was the most prevalent. The
32 majority of the isolates were classified as *emm* pattern E, followed by A-C3. No pattern D was found.
33 Among the virulence factors, the most prevalent were SpeG, Slo, C5a-peptidase and SPNA. Phage
34 encoded virulence genes were also found among the strains, such as *mf-2*, *SpeJ* and *SpeL*.

35 **Discussion:** The *emm1* type was the most prevalent while the 13 others M types were
36 distributed along the strains. No tissue tropism was found on the isolates. The virulence factors analysis
37 demonstrated that chromosomally and phage-encoded genes were found, which confers a potential for
38 high virulent micro-organisms.

39

40

41

42

43

44

45

46

47

48

49

50 Introduction

51 *Streptococcus pyogenes*, a Group A streptococci (GAS), is an important human pathogen that
52 causes a wide range of infections, from mild to severe invasive diseases. GAS are responsible for more
53 than 500,000 deaths annually, most of them occurring in low and middle-income countries (Steer et al.,
54 2016).

55 Considered one of the most important virulence factors, the M protein promotes host
56 interactions and adherence to human epithelial cells; specially helping bacteria to escape from host
57 immune response by inhibition of phagocytosis (McMillan et al., 2013). The discrimination of GAS
58 into more than 250 *emm* types is possible due to the sequencing of the hypervariable region of the
59 *emm* gene encoding the M protein (Friães et al., 2012). Although this is considered an effective method
60 to distinguish these micro-organisms, it still comprises a high number of *emm* types. Moreover, it has
61 contributed to the development of at least two more classifications systems. The first one is called *emm*
62 pattern and serves as a genotypic marker to classify GAS strains according to their tissue tropism; A-C
63 throat specialists, D skin specialists and E generalists. This method is based on the organization of *emm*
64 and *emm*-like genes located in the *mga* locus (McGregor et al., 2004). The second is called *emm* cluster
65 and is based on the entire sequence of the M protein. A phylogenetic tree was built using sequences of
66 175 different *emm* types, and they were classified by their sequence similarity. This classification was
67 able to divide the strains into two major clades, X and Y. The clade Y was divided in two main
68 subclades (Y1 and Y2), and these subclades were further subdivided into 48 *emm*-clusters along with
69 clade X (Sanderson-Smith et al., 2014).

70 Many virulence factors contribute to the pathogenesis of *S. pyogenes* diseases, each one with a
71 specific function and with a determined degree of importance (Bisno, Brito & Collins, 2003; Yang et
72 al., 2013). Superantigens (SAGs) are toxins capable of activating a large set of human T cells, resulting

73 in a massive production of proinflammatory cytokines (Reglinski & Sriskandan, 2014). The ability to
74 hemolyze red blood cells (β -hemolysis) is due to the presence of two distinct toxins streptolysin S
75 (SLS) and the unrelated large cholesterol-dependent, oxygen-sensitive streptolysin O (SLO) (Molloy et
76 al., 2011). Among this great variety of virulence factors described in GAS strains, some are directly
77 linked to phage carriage. The importance of phages for genetic variability, especially by transferring
78 virulence genes, has been extensively studied and is well consolidated (Banks, Beres & Musser, 2002).

79 Over the exposure, the aim of this study was to describe the genetic profile of clinical isolates of
80 *Streptococcus pyogenes*.

81

82 **Materials and Methods**

83 Bacterial strains were collected from two hospitals in the South of Brazil during the 2000-2013
84 period. This amount ended up to have most of the samples collected in the last two years. The
85 collection method used was convenience sampling depending on the hospital's availability. This study
86 was approved by the Ethics Committee of institutions involved. The clinical isolates were identified as
87 *Streptococcus pyogenes* by the API 20 Strep system (bioMérieux SA, Marcy L'Etoile, France) and by
88 16S rRNA conventional PCR (Lintges et al., 2007).

89 Fresh colonies, 24h growth on trypticase soy agar supplemented with 5% sheep blood were
90 used to DNA extraction by the QIAamp DNA Mini Kit (QIAGEN) as described by the manufacturers.
91 The DNA product was quantified in the NanoSpec (Nanometrics). Then, a PCR reaction for the *emm*
92 gene was performed in triplicate for each isolate, according to protocols available at the Centers for
93 Disease and Control (CDC) website (www.cdc.gov/streplab/). PCR products were purified with
94 Wizard® Genomic DNA Purification Kit (Promega) and measured to guarantee the correct DNA

95 concentration. The amount of DNA ranged from 20-40 ng/μl. The complete *emm* gene DNA was
96 sequenced in triplicate, forward and reverse, using primers described by CDC Strep Lab in a
97 concentration of 4 pmol. Three sequencing results from each isolate were analysed using the software
98 Geneious 9.1.8. The consensus sequence obtained was manually adjusted to ensure a minimum phred
99 score of 20 for each base. The nucleotide sequences were submitted to comparison with the CDC *emm*
100 database in order to obtain the correct *emm* type and *emm* cluster for each isolate. The genes listed in
101 Table 1 were used to analyse virulence factors, using a SYBR Green Master Mix and the platform
102 ABI7500 (Applied Biosystems). All reactions were performed in duplicate, with a positive and a
103 negative control for each primer. A positive amplification demonstrated similar melting curves in both
104 reactions compared to its respectively positive control ($T_m \pm 1^\circ\text{C}$). In addition, an analysis of the
105 quantification plot was made to ensure that the melting peak represented a true amplification.

106 The data analysis was mostly descriptive and no statistical analysis was performed due to the
107 limited number of isolates.

108

109

110 **Results**

111 The conventional PCR for the *emm* gene showed a positive reaction for all 25 isolates. BLASTn
112 results were acceptable regarding query cover (range from 91-100%), E-value (zero), and identity
113 (range from 93-100%).

114 Fourteen different *emm* types were identified among the 25 clinical isolates. The most frequent
115 was *emm1* 7/26 (28%), followed by *emm12*, *emm27*, *emm57*, *emm60* and *emm68* 2/25 each, (8%).
116 Other *emm* types were found in only 1/25 (4%) strains, namely *emm8*, *emm22*, *emm44*, *emm58*,
117 *emm59*, *emm73*, *emm90* and *emm92*. The *emm* pattern analysis demonstrated that 15/25 (60%) of the
118 isolates were classified as *emm* pattern type E (*emm* cluster, E2, E3, E4 and E6) while 10/25 (40%)

119 were pattern A-C (*emm* cluster, A-C3, A-C4 and M57). No isolate was classified as *emm* pattern D.
120 The sites of isolation were as follows: skin lesion (8/25), blood (7/25), oropharynx (6/25) and the last
121 four clinical samples were obtained from pleural fluid, sputum, and abscess(2).

122 Regarding the 23 virulence factors, twelve belonged to the superantigens class, and were
123 distributed as follows: *speA1-3* (40%), *speA-5* (52%), *speC* (44%), *speJ* (76%), *speK* (24%), *speL*
124 (88%), *speH* (56%), *speI* (64%), *speM* (68%), *smeZ* (80%) and *ssa* (28%). The only SA_g present in all
125 clinical specimens was *speG*, and the only absent was the *speA4* allele. Among the non-SA_gs virulence
126 genes, three mitogenic factors were verified, and the most frequent was *mf2* (92%), followed by *mf3*
127 (68%) and *dnaseB* (*SpeF*) (56%). The prevalence of the two-serum opacity factor portions were: *sofC*
128 (68%) and *sofN* (48%). The last six virulence factors analyzed were reported individually. Three of
129 them were found in all isolates: streptolysin O (*slo*), C5a-peptidase (*scpa*), and a nuclease A (*spna*).
130 The Dnase (*sda1*) was present in 88% of the isolates, and the NAD-glycohydrolase (*nga*) in 96%. The
131 streptococcal inhibitor of the complement (*sic*) was present in 80% of the isolates.

132 The superantigens were similarly distributed among the *emm* types and the sites of infection,
133 showing the diversity of the isolates included in this study (Fig 1).

134

135 Discussion

136 *Streptococcus pyogenes* is estimated to be responsible for over 600 million new cases of
137 pharyngitis each year. In addition to triggering autoimmune sequelae, such as acute rheumatic fever,
138 nasopharyngeal infection with *S. pyogenes* represents the principal reservoir for invasive diseases such
139 as necrotizing fasciitis, pneumonia and toxic shock syndrome (Osowicki et al., 2018).

140 Numerous typing schemes have been used to characterise and measure the genetic diversity
141 among isolates of *S. pyogenes*. One of the most used is *emm* typing, in which the hypervariable portion
142 of the *emm* gene encoding M protein is sequenced (Steer et al., 2009). Recently, a study from São

143 Paulo, Brazil, demonstrated that the most predominant *emm* types were *emm1*, *emm6*, *emm12*, *emm22*,
144 *emm77* and *emm87* (De Amicis et al., 2014). Although our sample size was not adequate for an
145 epidemiological study, we were able to verify that *emm1* was predominant. However, the other 13 *emm*
146 types on this work did not stand out and were found to be well distributed among the strains.

147 Sixty percent of the isolates were classified as *emm* pattern E and 40% were classified as
148 pattern A-C. This classification has been shown to correlate significantly with tissue tropism; patterns
149 A-C are the throat specialists, D is the skin specialists and E is generalists. However, only a small
150 proportion of specific *emm* pattern strains have been extensively studied (Chiang-Ni et al., 2016). Here,
151 even with a variety of infections sites, no pattern D was found, and no relatedness was found among the
152 site of infection and the *emm* pattern or even the *emm* cluster.

153 *Streptococcus pyogenes* is recognized by its arsenal of virulence factors, which targets and
154 impairs the immune system. Many of these are scattered throughout the genome, and are not strictly
155 part of pathogenicity island. For the most part, these virulence genes are conserved amongst strains,
156 apart from the ones carried by phages (Ibrahim et al., 2016). In our study, four virulence genes were
157 present in all 25 isolates, a superantigen (*speG*), a streptolysin O (*slo*), C5a-peptidase (*scpa*), and a
158 nuclease A (*spna*). The first three are usually present within the GAS chromosomes while the last one is
159 prophage encoded. The mitogenic factor (*mf2*) and the superantigens (*speL* and *speJ*) are all phage
160 encoded, and were also present in a high number of isolates. In addition, the streptococcal inhibitor of
161 complement (*sic*), the NAD-glycohydrolase (*nga*), which is directly linked to SLO production and the
162 superantigen SMEZ, are all chromosomally encoded and were also present in a high number of isolates
163 (Banks, Beres & Musser, 2002; Ibrahim et al., 2016). These results can be considered evidence that
164 horizontal gene transfer occurs among our isolates and that most of them have a high number of
165 virulence factors, which demonstrates a potential to cause severe diseases.

166 An important review has brought to light many studies about SAGs and its association with
167 invasive and non-invasive diseases and asymptomatic carriage. However, it is still a controversial topic,
168 because associations are shown in some studies but not in others (Commons et al., 2014). In our study,
169 SAGs were distributed along the diverse clinical isolates without showing a pattern, which could led us
170 to believe in associations between them and *emm* types or site of infection.

171 This investigation was performed with a number of strains that is considered low for an
172 epidemiological approach. However, we believe that the results are in accordance with our aims, and
173 also could be used as preliminary data for other studies.

174 **Conclusions**

175 In summary, the *emm* types found here are too diverse to define a tendency. The *emm* pattern
176 and *emm* cluster analysis demonstrated that the majority of the isolates were classified as generalists
177 considering the site of infection, and no isolate was classified as skin specialists. The analysis of the
178 virulence factors demonstrated that chromosomally and phage-encoded genes were found, which
179 confers a potential for high virulent micro-organism. No relatedness could be found among virulence
180 factors and *emm* typing or site of infection, reinforcing the controversial character of this subject.

181

182

183

184

185

186

187 **References**

- 188 De Amicis KM, Freschi de Barros S, Alencar RE, Postól E, Martins C de O, Arcuri HA, Goulart C,
189 Kalil J, Guilherme L. 2014. Analysis of the coverage capacity of the StreptInCor candidate
190 vaccine against *Streptococcus pyogenes*. *Vaccine* 32:4104–4110. DOI:
191 10.1016/j.vaccine.2013.08.043.
- 192 Banks DJ, Beres SB, Musser JM. 2002. The fundamental contribution of phages to GAS evolution,
193 genome diversification and strain emergence. *Trends in Microbiology*. DOI: 10.1016/S0966-
194 842X(02)02461-7.
- 195 Bisno AL, Brito MO, Collins CM. 2003. Molecular basis of group A streptococcal virulence. *Lancet*
196 *Infectious Diseases* 3:191–200. DOI: 10.1016/S1473-3099(03)00576-0.
- 197 Chiang-Ni C, Zheng P-X, Wang S-Y, Tsai P-J, Chuang W-J, Lin Y-S, Liu C-C, Wu J-J. 2016.
198 Epidemiology Analysis of *Streptococcus pyogenes* in a Hospital in Southern Taiwan by Use of the
199 Updated emm Cluster Typing System. *Journal of clinical microbiology* 54:157–62. DOI: 10.1128/
200 JCM.02089-15.
- 201 Commons RJ, Smeesters PR, Proft T, Fraser JD, Robins-Browne R, Curtis N. 2014. Streptococcal
202 superantigens: categorization and clinical associations. *Trends in Molecular Medicine* 20:48–62.
203 DOI: 10.1016/J.MOLMED.2013.10.004.
- 204 Friães A, Pinto FR, Silva-Costa C, Ramirez M, Melo-Cristino J, Portuguese Group for the Study of
205 Streptococcal Infections. 2012. Group A streptococci clones associated with invasive infections
206 and pharyngitis in Portugal present differences in emm types, superantigen gene content and
207 antimicrobial resistance. *BMC microbiology* 12:280. DOI: 10.1186/1471-2180-12-280.
- 208 Ibrahim J, Eisen JA, Jospin G, Coil DA, Khazen G, Tokajian S. 2016. Genome Analysis of
209 *Streptococcus pyogenes* Associated with Pharyngitis and Skin Infections. *PLOS ONE*
210 11:e0168177. DOI: 10.1371/journal.pone.0168177.
- 211 Lintges M, Arlt S, Uciechowski P, Plümäkers B, Reinert RR, Al-Lahham A, Lütticken R, Rink L. 2007.
212 A new closed-tube multiplex real-time PCR to detect eleven superantigens of *Streptococcus*
213 *pyogenes* identifies a strain without superantigen activity. *International journal of medical*
214 *microbiology: IJMM* 297:471–8. DOI: 10.1016/j.ijmm.2007.03.015.
- 215 McGregor KF, Spratt BG, Kalia A, Bennett A, Bilek N, Beall B, Bessen DE. 2004. Multilocus
216 sequence typing of *Streptococcus pyogenes* representing most known emm types and distinctions
217 among subpopulation genetic structures. *Journal of bacteriology* 186:4285–94. DOI:
218 10.1128/JB.186.13.4285-4294.2004.
- 219 McMillan DJ, Drèze P-A, Vu T, Bessen DE, Guglielmini J, Steer AC, Carapetis JR, Van Melder L,
220 Sriprakash KS, Smeesters PR, Group the MPS. 2013. Updated model of group A *Streptococcus* M
221 proteins based on a comprehensive worldwide study. *Clinical microbiology and infection: the*


- 222 *official publication of the European Society of Clinical Microbiology and Infectious Diseases*
223 19:E222-9. DOI: 10.1111/1469-0691.12134.
- 224 Molloy EM, Cotter PD, Hill C, Mitchell DA, Ross RP. 2011. Streptolysin S-like virulence factors: The
225 continuing saga. *Nature Reviews Microbiology* 9:670–681. DOI: 10.1038/nrmicro2624.
- 226 Osowicki J, Vekemans J, Kaslow DC, Friede MH, Kim JH, Steer AC. 2018. WHO/IVI global
227 stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting
228 held on 12–13 December 2016. *Vaccine*. DOI: 10.1016/J.VACCINE.2018.02.068.
- 229 Reglinski M, Sriskandan S. 2014. The contribution of group A streptococcal virulence determinants to
230 the pathogenesis of sepsis. *Virulence* 5:127–136. DOI: 10.4161/viru.26400.
- 231 Sanderson-Smith M, De Oliveira DMP, Guglielmini J, Mcmillan DJ, Vu T, Holien JK, Henningham A,
232 Steer AC, Beall BW, Walker MJ, Parker MW. 2014. A Systematic and Functional Classification of
233 Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine
234 Development. *The Journal of infectious diseases*:1325–38. DOI: 10.1093/infdis/jiu260.
- 235 Steer AC, Carapetis JR, Dale JB, Fraser JD, Good MF, Guilherme L, Moreland NJ, Mulholland EK,
236 Schodel F, Smeesters PR. 2016. Status of research and development of vaccines for Streptococcus
237 pyogenes. *Vaccine* 34:2953–2958. DOI: 10.1016/j.vaccine.2016.03.073.
- 238 Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. 2009. Global emm type distribution of group A
239 streptococci: systematic review and implications for vaccine development. *The Lancet Infectious*
240 *Diseases* 9:611–616. DOI: 10.1016/S1473-3099(09)70178-1.
- 241 Yang P, Peng X, Zhang D, Wu S, Liu Y, Cui S, Lu G, Duan W, Shi W, Liu S, Li J, Wang Q. 2013.
242 Group a Streptococcus strains circulating during scarlet fever epidemic, Beijing, China, 2011.
243 *Emerging Infectious Diseases* 19:909–915. DOI: 10.3201/eid1906.121020.
244

245 Table 1. Primers used in this study.

Target	Primer Sequences	T _m (°C)	References
<i>16S rRNA</i>	F: GTGAGTAACGCGTAGGTAACCTACCTCATAG R: CCCAGGCGGAGTGCTTAATG	–	Lintges et. al, 2007
<i>spec</i>	F: GGTAATTTTTCAACGACACACATTA R: TGTTGAGATTCTCCGAAATAATAGAT	74.27	Lintges et. al, 2007
<i>spcg</i>	F: GCTATGGAAGTCAATTAGCTTATGCAGAT R: TTATGCGAACAGCCTCAGAGG	74.87	Lintges et. al, 2007
<i>spej</i>	F: CAATTAATTACGCATACGAAATCATAACAGTA R: ACGAGTAAATATGTACGGAAGACCAAAAATA	73.51	Lintges et. al, 2007
<i>spek</i>	F: TATCGCTTGCTCTATACACTACTGAGAGT R: CCAAAGTGTAGTATTTTCATCCGTATTA	73.27	Lintges et. al, 2007
<i>spel</i>	F: GGACGCAAGTTATTATGGATGCTCA R: TTAATAAAGTCAGCACCTTCTCTTTCTC	73.95	Lintges et. al, 2007
<i>spea1-3,5</i>	F: GGTATTTGCTCAACAAGACCCCGAT R: TGTGTTTGAGTCAAGCGTTTCATTATCT	77.29	Lintges et. al, 2007
<i>speh</i>	F: TCTATCTGCACAAGAGGTTTGTGAATGTCCA R: GCATGCTATTAAGTCTCCATTGCCAAAA	78.71	Lintges et. al, 2007
<i>spei</i>	F: AAGGAAAAATAAATGAAGGTCCGCCAT R: TCGCTTAAAGTAATACCTCCATATGAATTCTTT	75.10	Lintges et. al, 2007
<i>spem</i>	F: GCTTTAAGGAGGAGGAGGTTGATATTATGCTCTA R: CAAAGTGACTTACTTTACTCATATCAATCGTTTC	62.13	Lintges et. al, 2007
<i>smcz</i>	F: CAATAATTTCTCGTCTGTGTTGGAT R: GATAAGGCGTCATTCCACCATAG	78.19	Lintges et. al, 2007
<i>ssa</i>	F: AATTATTATCGATTAGTGTTTTTGCAAGTA R: AGCCTGTCTCGTACGGAGAATTATTGAACTC	62.67	Lintges et. al, 2007
<i>spea1-4</i>	F: CAAGAAGTATTGCTCAACAAGACCCCA R: TTAGATGGTCCATTAGTATATAGTTGCTTGTIATC	72.28	Lintges et. al, 2007
<i>sof_N</i>	F: AGCCTGACACACTTGGTTGGGT R: GCGGCGCTCAAAATGGTGTGGT	82.89	This study.
<i>sof_C</i>	TCGGCGCCTTCGTCAATTTGCT ACCCCAAGCACAGACAGCTCCA	78.37	This study.
<i>nga</i>	F: AGCCTGTGTCAGAGGTCACCTTTGG R: GGCAACCAGGAACGTTGAGCGA	83.21	This study.
<i>spna</i>	F: ACAGCAGGTGTTTTGTTGGACCT R: ACTGCTTTCTCTTGCATTTACAGCCT	78.04	This study.
<i>dnase</i>	F: AGTCCAGCCTGCGGGGTTTTGA R: ACTGCACTGGCAGCACAACACA	63.15	This study.
<i>sda1</i>	F: ACGGAAATGTTTCGTAACGGCTACC R: GTGCATCCGTGTCAGGCTCGTT	78.91	This study.
<i>mf2</i>	F: GCACCTGTGTTTAGCCAGGCTGT R: TGACCCTGTGGGATGGCACAAC	81.24	This study.
<i>mf3</i>	F: ACGAAGGCGACTGAGACACCAG R: TGGCCACGGTCCATTAACCAAGT	82.60	This study.
<i>slo</i>	F: TGTCAGCAATGAAGTCCGCCA R: GCGGTTTTCTGGCACACGAGG	78.23	This study.
<i>sic</i>	R: TGAGTGGCCTCAGTGAATGGCT F: ACGGGTCTTGCCCCAAAGCTA	83.11	This study.
<i>scpa</i>	R: GCTGTCGATCAAGAGCACGGCA	84.20	This study.

246 Primers and its respective melting temperatures used in the Real-time reactions.

247 Figure 1.



249 Schematic representation of the virulence factors distribution among all 25 clinical isolates of *S. pyogenes*. The tree was
 250 built based on the presence/absence of each virulence gene using similarity via the Jaccard method. Also, a representation
 251 of the main parameters used to describe the genetic profile of the micro-organisms included in this study.